Učitavanje...
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
BACKGROUND: High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to tre...
Spremljeno u:
| Izdano u: | BMC Neurol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4236650/ https://ncbi.nlm.nih.gov/pubmed/25179671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-014-0169-0 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|